Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors

Written by Customer Service on March 31, 2024. Posted in Public Companies.

Palm Beach Gardens, FL, and Tokyo, Japan, March 31, 2024 (GLOBE NEWSWIRE) — Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for degenerative eye diseases today announced the nomination to its Board of Directors of Dr. Theresa Heah. Dr. Heah is expected to join its Board of Directors immediately as an independent director. In addition to other Board duties Dr. Heah will serve on the newly created Clinical Development Committee of the Board. About Dr. Theresa Heah Dr. Heah recently served as the Chief Executive Officer and a member of the Board of Directors at Intergalactic Therapeutics an Apple Tree Partners company. She serves as an advisor to several venture capital firms and ophthalmology companies; and has recently become the Chief...

Total number of shares and voting rights in Zealand Pharma at March 31, 2024

Written by Customer Service on March 31, 2024. Posted in Public Companies.

Company announcement – No. 21 / 2024 Total number of shares and voting rights in Zealand Pharma at March 31, 2024 Copenhagen, Denmark, March 31, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital. In Company announcement No. 11/2024 from March 5, 2024, and in company announcement No. 19/2024, from March 26,2024, Zealand announced an increase in share capital relating to exercise of employee warrants. Following these announcements, the table below lists the total number of...

CH Auto Technology Corporation Ltd. Completes Business Combination

Written by Customer Service on March 31, 2024. Posted in Mergers And Acquisitions.

BEIJING and NEW YORK, March 30, 2024 (GLOBE NEWSWIRE) — CH Auto Technology Corporation Ltd. (“CHATC”), a company formed under the laws of the Peoples Republic of China (“PRC”), an electric vehicle manufacturing and design service company based in China, and Mountain Crest Acquisition Corp. IV (Nasdaq: MCAF), a Delaware corporation that was a publicly-traded special purpose acquisition company (“MCAF”), today announced that on March 28, 2024, the closing of their business combination transaction occurred, pursuant to an Agreement and Plan of Merger (as amended and restated on December 23, 2022 and further amended on March 1, 2023, the “Merger Agreement”) by and among the CHATC, MCAF, CH Auto, Inc., a Cayman Islands exempted company (“CH Auto”) and CH-Auto Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of CH...

CORRECTION — AEON Biopharma Announces Redemption of Public Warrants

Written by Customer Service on March 31, 2024. Posted in Public Companies.

IRVINE, Calif., March 30, 2024 (GLOBE NEWSWIRE) — Regarding a release issued under the same headline on March 29, 2024 by AEON Biopharma, Inc. (NYSE: AEON; AEON.WS), please note that in the first paragraph it incorrectly referenced March 29, 2024 as the Redemption Date. The Redemption Date is April 29, 2024. March 29, 2024 is the date on which the notice of redemption was delivered to warrant holders. The corrected release follows: AEON Biopharma, Inc. (NYSE: AEON; AEON.WS) (“AEON” or “the Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that the Company will redeem all of its outstanding warrants (the “Public Warrants”) to purchase shares of the Company’s Class A common stock, par value...

Day: March 31, 2024